ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,872.16
-2.95%
Dow Jones
42,326.87
-2.58%
US Dollar vs MXN
20.33005
-0.31%
Brent Oil
72.91
0.24%
Bitcoin
102,347.13
2.28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Clearmind Medicine Inc (CMND)

  7. Clearmind Medicine Inc (CMND) Noticias

CMND

Clearmind Medicine (CMND)

Clearmind Medicine Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CMND
FechaHoraFuenteTítuloSímboloCompañía
16/12/202407:37GlobeNewswire Inc.Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ FormatNASDAQ:CMNDClearmind Medicine Inc
09/12/202416:12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMNDClearmind Medicine Inc
06/12/202416:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMNDClearmind Medicine Inc
10/10/202407:07GlobeNewswire Inc.Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteNASDAQ:CMNDClearmind Medicine Inc
30/09/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMNDClearmind Medicine Inc
24/09/202415:30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CMNDClearmind Medicine Inc
16/09/202415:06GlobeNewswire Inc.Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyNASDAQ:CMNDClearmind Medicine Inc
12/09/202407:20GlobeNewswire Inc.Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
06/09/202406:55GlobeNewswire Inc.Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
06/09/202406:55GlobeNewswire Inc.SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
29/08/202415:25GlobeNewswire Inc.Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination TreatmentNASDAQ:CMNDClearmind Medicine Inc
21/08/202415:11GlobeNewswire Inc.Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior TreatmentNASDAQ:CMNDClearmind Medicine Inc
16/08/202415:14GlobeNewswire Inc.Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental DisordersNASDAQ:CMNDClearmind Medicine Inc
06/08/202407:57GlobeNewswire Inc.Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss DrugNASDAQ:CMNDClearmind Medicine Inc
06/08/202407:57GlobeNewswire Inc.SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss DrugNASDAQ:CMNDClearmind Medicine Inc
31/07/202406:44GlobeNewswire Inc.Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking ResearchNASDAQ:CMNDClearmind Medicine Inc
19/07/202406:55GlobeNewswire Inc.Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage ProductNASDAQ:CMNDClearmind Medicine Inc
16/07/202408:02GlobeNewswire Inc.Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for AlcoholismNASDAQ:CMNDClearmind Medicine Inc
16/07/202405:03GlobeNewswire Inc.SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight LossNASDAQ:CMNDClearmind Medicine Inc
16/07/202405:03GlobeNewswire Inc.Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossNASDAQ:CMNDClearmind Medicine Inc
12/07/202407:02GlobeNewswire Inc.Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 ConferenceNASDAQ:CMNDClearmind Medicine Inc
28/06/202406:55GlobeNewswire Inc.Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors TreatmentNASDAQ:CMNDClearmind Medicine Inc
20/06/202406:57GlobeNewswire Inc.Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
11/06/202406:44GlobeNewswire Inc.Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based DrinkNASDAQ:CMNDClearmind Medicine Inc
10/05/202407:24GlobeNewswire Inc.Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductNASDAQ:CMNDClearmind Medicine Inc
07/05/202406:46GlobeNewswire Inc.Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentNASDAQ:CMNDClearmind Medicine Inc
30/04/202415:15GlobeNewswire Inc.Clearmind Applies to Cease Being a Reporting Issuer in CanadaNASDAQ:CMNDClearmind Medicine Inc
17/04/202406:49GlobeNewswire Inc.Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersNASDAQ:CMNDClearmind Medicine Inc
10/04/202406:17GlobeNewswire Inc.Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersNASDAQ:CMNDClearmind Medicine Inc
09/04/202407:07GlobeNewswire Inc.Clearmind Medicine CEO Issues Letter to ShareholdersNASDAQ:CMNDClearmind Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:CMND

Su Consulta Reciente

NYSE
CSS
CSS Industries
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados